As post-pandemic trends come into view, we’ll watch for opportunities to adapt so that, together, we can anticipate and navigate new challenges.
We've updated our website privacy notice. Review privacy notice
We've updated our website privacy notice. Review privacy notice
As post-pandemic trends come into view, we’ll watch for opportunities to adapt so that, together, we can anticipate and navigate new challenges.
We continue to monitor the effects of the COVID-19 pandemic:
For the first time ever, specialty drug spend surpassed 50% of overall pharmacy spend among commercial plans. We expect this trend to continue as specialty spending could increase 10-15% over the next few years, influenced mainly by existing medications for inflammatory conditions and new drugs for cancer and rare conditions. We anticipate some downward pressure as a result of generic availability for HIV.
Here are four conditions to focus on when it comes to influencing specialty spending:
annual cost to payers for one patient with hereditary angioedema, a rare but potentially life-threatening genetic condition affecting 1 in 50,000